资源描述：
《75例耐药性肺结核病人临床治疗方法及疗效探讨》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。
1、75例耐药性肺结核病人临床治疗方法及疗效探讨戴汶灼古米娜艾迪杰何康唐盛瑞武警新疆总队医院R的探讨耐药肺结核病人治疗的有效方案，以提高临床治愈率。方法在药敏试验基础上，选用利福喷汀+对氨基水杨酸+莫西沙星+阿米卡星+丙硫异烟胺+胸腺五肽，总疗程12个月。定期开展痰菌检查、拍摄X线片或CT片，观察药物不良反应。结果病人治疗前，对一线抗痨药物单药耐药率为16.24%、2种药物耐药率为42.74%、3种及以上药物耐药率为41.03%;疗程结束吋，74例资料完整病人屮，66例（89.19%）痰菌阴转，71例（95.95%）病灶较治疗前明显吸收;8
2、例痰菌未阴转者，经调整抗痨方案，并延长治疗一年，其痰菌全部阴转;75例病人中除1例因合并症死亡未完成疗程外，其余74例均按医嘱完成了全程治疗，规范治疗率100.00%。结论根据药敏试验结果科学拟定用药方案，可提高耐药肺结核病人的痰菌阴转率，促进肺部病灶吸收。关键词：耐药;肺结核;治疗;戴汶灼（1981-）,女，主管药师，从事药剂工作，E-mail:ml3992740510@163.com2017-03-15Clinicaltreatmentmethodandcurativeeffectof75patientswithdrugresist
3、antpulmonarytuberculosisDAIWenzhuoGUMinaAIDiiieHEKangTANGShengruiArmedPoliceCorpsHospital;Abstract：ObjectiveToexploretheeffectivetreatmentofdrugresistantpulmonarytuberculosispatientsinordertoimprovetheclinicalcurerate.MethodsBasedonthedrugsensitivitytest,selectionofrifap
4、entine+PAS+moxifloxacin+Amikacin+Protionamide+microcard,thetotalcourseof12months.Regularlycarryoutsputumbacterialexamination,XfilmorCTfilm，adversedrugreactionsobserved.ResultsPatientsbeforetreatmenttofirst-lineantituberculosisdrugssingledrugresistanceratewas16.24%,twokin
5、dsofdrugresistanceratewas42.74%，morethanthreekindsofdrugresistanceratewas41.03%;attheendofthetreatment,74casesofcompletedataofpatients,66cases(89.19%)sputumnegative,71cases(95.95%)werecomparedwiththosebeforetreatmentapparentabsorption;8casesofsputumnegativeconversion,adj
6、ustedantituberculosisscheme,andtheextensionof1yearsoftreatment,thesputumnegative;74patientswerecompletedaccordingtotheprescribedtherapy,standardizedtreatmentrate100.00%.ConclusionDrugresistantpulmonarytuberculosisisveryharmfulanddifficulttotreat.However,aslongasdocatchdr
7、ugsensitivetest,selectionofsensitiveantituberculosisdrugs,strengthensupervision,preventionanddisposalofpositivesideeffectsofkeylinks,doareasonabletreatmentplan，usestandard,sustained,anddurationoftreatmentwithmoderate,canobtaingoodtherapeuticeffect.Keyword：Drugresistance;
8、Pulmonarytuberculosis;Treatment;Received：2017-03-152013年全球结核新发病例以及复治病例的耐药率分别为3.5%和20.5%（其中广泛耐药占9%），而我国则
